# Right Heart Failure â€“ Enhanced RRT Protocol with Evidence-Based Integration

**Primary Guidelines:** 
- UpToDate Clinical Decision Support - Right Heart Failure Management 2025[1][2]
- 2024 Pulmonary Arterial Hypertension Treatment Guidelines[3]
- 2024 ESC Heart Failure Guidelines - Right Heart Focus
- Virtua Health System Advanced HF Protocol Integration

**Official Sources:** 
- UpToDate Right Heart Failure: Causes and Management[1]
- UpToDate Treatment and Prognosis of Pulmonary Arterial Hypertension[2]

## ENHANCED PATHOPHYSIOLOGY-DRIVEN MERMAID ALGORITHM

~~~mermaid
graph TD
    A["ğŸ«€ RHF Recognition<br/>Systemic Venous Congestion"] --> B["ğŸš¨ ABCs + Hemodynamic<br/>Assessment"]
    
    B --> C["ğŸ“Š Immediate Stabilization<br/>O2 + Access + Monitoring"]
    
    C --> D{"ğŸ’“ Hemodynamic<br/>Stability?"}
    
    D -->|UNSTABLE| E["ğŸ¥ ICU Transfer<br/>Invasive Monitoring"]
    D -->|STABLE| F["ğŸ” Systematic Etiology<br/>Assessment"]
    
    E --> G["ğŸ“ˆ Swan-Ganz Catheter<br/>Hemodynamic Optimization"]
    F --> H{"ğŸ¯ Primary<br/>RHF Etiology?"}
    
    G --> I["ğŸ’ª RV Support Triad<br/>Preload/Afterload/Contractility"]
    
    H -->|PAH GROUP 1| J["ğŸ« PAH-Specific Therapy<br/>Combination Approach"]
    H -->|LEFT HEART DISEASE| K["ğŸ’” Optimize LV Function<br/>GDMT + Volume"]
    H -->|PULMONARY DISEASE| L["ğŸ”¬ Treat Lung Disease<br/>+ O2 Optimization"]
    H -->|CTEPH/PE| M["ğŸ©¸ Anticoagulation<br/>+ Intervention"]
    H -->|RV INFARCTION| N["âš¡ Maintain Preload<br/>+ Reperfusion"]
    H -->|CONGENITAL/VALVE| O["ğŸ”§ Structural Intervention<br/>Surgical Planning"]
    
    I --> P{"ğŸ“Š Adequate RV<br/>Performance?"}
    J --> Q["ğŸ†• Advanced PAH Rx<br/>Sotatercept Era"]
    K --> R["ğŸ’Š SGLT2i + ARNI<br/>RV-Protective Therapy"]
    L --> S["ğŸ« Lung-Specific<br/>Management"]
    M --> T["ğŸ”„ Reperfusion vs<br/>Endarterectomy"]
    N --> U["ğŸ©¸ Urgent Reperfusion<br/>+ RV Support"]
    O --> V["âš™ï¸ Surgical/Transcatheter<br/>Intervention"]
    
    P -->|YES| W["ğŸ“‰ Wean Support<br/>Transition Strategy"]
    P -->|NO| X["âš™ï¸ Mechanical Support<br/>RVAD/ECMO/Impella"]
    
    Q --> Y{"ğŸ¯ PAH Response<br/>Assessment?"}
    R --> Z["ğŸ“Š HF Response<br/>Monitoring"]
    S --> Z
    T --> AA["ğŸ”¬ Post-Intervention<br/>Assessment"]
    U --> AA
    V --> AA
    
    X --> BB["ğŸ”§ MCS Management<br/>Bridge Decisions"]
    
    Y -->|GOOD| CC["ğŸ“ˆ Continue Therapy<br/>Long-term Management"]
    Y -->|POOR| DD["ğŸ†˜ Advanced Options<br/>Transplant/Novel Rx"]
    Z --> EE["ğŸ“‹ Disposition<br/>Based on Response"]
    AA --> EE
    W --> EE
    
    BB --> FF{"ğŸŒ‰ Bridge to<br/>What?"}
    
    FF -->|RECOVERY| GG["ğŸ”„ Weaning Protocol<br/>Recovery Support"]
    FF -->|TRANSPLANT| HH["ğŸ«€ Transplant Evaluation<br/>Advanced HF Center"]
    FF -->|DESTINATION| II["ğŸ  Long-term MCS<br/>Palliative Focus"]
    
    CC --> JJ["ğŸ  Outpatient<br/>PAH Management"]
    DD --> KK["ğŸ¥ Advanced HF Center<br/>Experimental Therapies"]
    EE --> LL["ğŸ“Š Appropriate Level<br/>of Care"]
    GG --> LL
    HH --> MM["ğŸ”¬ Transplant<br/>Workup/Listing"]
    II --> NN["ğŸ¤ Palliative Care<br/>QOL Focus"]
    
    JJ --> OO["ğŸ“‹ Specialist<br/>Follow-up"]
    KK --> MM
    LL --> OO
    MM --> PP["ğŸ¯ Long-term<br/>Management Plan"]
    NN --> PP
    
    OO --> QQ["âœ… RHF Protocol<br/>Complete"]
    PP --> QQ
    
    style A fill:#ffcccc
    style E fill:#ff6666
    style G fill:#ffaaaa
    style I fill:#fff2cc
    style X fill:#ff8888
    style BB fill:#ccffcc
    style DD fill:#e6ccff
    style QQ fill:#ccffee
~~~

## COMPREHENSIVE EVIDENCE-BASED CARD SYSTEM

### Card 0 â€“ Advanced RHF Recognition (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ«€ RIGHT HEART FAILURE RECOGNITION      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ“Š Clinical Definition[1]**:          â”‚
â”‚ â€¢ Symptoms and signs caused by RV dysfunctionâ”‚
â”‚ â€¢ Impaired ability to perfuse lungs at normal CVPâ”‚
â”‚ â€¢ NOT synonymous with RV dysfunction aloneâ”‚
â”‚                                         â”‚
â”‚ **ğŸ” Recognition Criteria (Evidence-Based)[1]**:â”‚
â”‚ â€¢ **Signs**: JVP elevation, hepatomegaly, peripheral edemaâ”‚
â”‚ â€¢ **Symptoms**: Exertional dyspnea, fatigue, dizzinessâ”‚
â”‚ â€¢ **Hemodynamics**: Low CO, elevated CVP â”‚
â”‚ â€¢ **Imaging**: RV dysfunction on echo   â”‚
â”‚                                         â”‚
â”‚ **ğŸ“‹ RHF Clinical Syndrome Components[1]**:â”‚
â”‚ â€¢ **Volume overload**: Peripheral edema, ascitesâ”‚
â”‚ â€¢ **Low output**: Fatigue, exercise intoleranceâ”‚
â”‚ â€¢ **Organ congestion**: Hepatic, renal, GIâ”‚
â”‚ â€¢ **Poor perfusion**: Cool extremities  â”‚
â”‚                                         â”‚
â”‚ **âš ï¸ Critical Recognition Points**:     â”‚
â”‚ â€¢ May occur without LV involvement     â”‚
â”‚ â€¢ Can be acute or chronic presentation â”‚
â”‚ â€¢ Often involves multiple etiologies   â”‚
â”‚ â€¢ High mortality if unrecognized       â”‚
â”‚                                         â”‚
â”‚ [Next: Hemodynamic assessment â–¶]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1 â€“ Systematic Etiology Classification (Node F â†’ H)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” COMPREHENSIVE RHF ETIOLOGY FRAMEWORK â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ« Group 1: Pulmonary Arterial Hypertension[1]**:â”‚
â”‚ â€¢ **Idiopathic PAH**: Most studied form â”‚
â”‚ â€¢ **Associated PAH**: CTD, CHD, drugs, toxinsâ”‚
â”‚ â€¢ **Heritable PAH**: BMPR2, other mutationsâ”‚
â”‚ â€¢ **Drug/toxin-induced**: Methamphetamines, appetite suppressantsâ”‚
â”‚                                         â”‚
â”‚ **ğŸ’” Group 2: Left Heart Disease[1]**:  â”‚
â”‚ â€¢ **HFrEF/HFmrEF**: LVEF â‰¤40-49%       â”‚
â”‚ â€¢ **HFpEF**: LVEF â‰¥50% (challenging diagnosis)â”‚
â”‚ â€¢ **Valvular disease**: Mitral/aortic stenosis/regurgitationâ”‚
â”‚ â€¢ **Atrial myxoma**: Obstructive lesion â”‚
â”‚                                         â”‚
â”‚ **ğŸ« Group 3: Lung Disease/Hypoxemia[1]**:â”‚
â”‚ â€¢ **COPD**: Most common chronic cause   â”‚
â”‚ â€¢ **ILD**: Progressive pulmonary fibrosisâ”‚
â”‚ â€¢ **OSA**: Underrecognized contributor  â”‚
â”‚ â€¢ **High-altitude exposure**: Chronic hypoxiaâ”‚
â”‚                                         â”‚
â”‚ **ğŸ©¸ Group 4: CTEPH[1]**:               â”‚
â”‚ â€¢ **Chronic thromboembolic**: Post-PE sequelaeâ”‚
â”‚ â€¢ **Pulmonary artery sarcoma**: Rare malignancyâ”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Group 5: Multifactorial[1]**:      â”‚
â”‚ â€¢ **Sarcoidosis**: Granulomatous diseaseâ”‚
â”‚ â€¢ **Schistosomiasis**: Global health concernâ”‚
â”‚ â€¢ **Complex congenital**: Multiple factorsâ”‚
â”‚                                         â”‚
â”‚ [Next: Etiology-specific management â–¶] â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Advanced Hemodynamic Monitoring (Node G â†’ I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ SWAN-GANZ CATHETER INTEGRATION       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ Indications for RHC[1]**:          â”‚
â”‚ â€¢ Hemodynamically unstable RHF         â”‚
â”‚ â€¢ Uncertain volume status              â”‚
â”‚ â€¢ Need for vasopressor/inotrope guidanceâ”‚
â”‚ â€¢ Differentiate pre vs post-capillary PHâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Key Hemodynamic Parameters[1]**:   â”‚
â”‚ â€¢ **RAP (CVP)**: Normal 2-8 mmHg       â”‚
â”‚ â€¢ **PAP**: Systolic/Diastolic/Mean     â”‚
â”‚ â€¢ **PCWP**: <15 mmHg (pre-capillary PH)â”‚
â”‚ â€¢ **Cardiac output**: Thermodilution/Fickâ”‚
â”‚ â€¢ **PVR**: Calculate (mPAP-PCWP)/COÃ—80  â”‚
â”‚                                         â”‚
â”‚ **ğŸ¯ RHF-Specific Targets[1]**:         â”‚
â”‚ â€¢ RAP: 8-12 mmHg (avoid overdistension)â”‚
â”‚ â€¢ Cardiac index: >2.2 L/min/mÂ²         â”‚
â”‚ â€¢ Mixed venous O2: >60%                 â”‚
â”‚ â€¢ PVR: <5 Wood units if treatable      â”‚
â”‚                                         â”‚
â”‚ **âš ï¸ Interpretation Challenges[1]**:    â”‚
â”‚ â€¢ Pericardial constraint effects       â”‚
â”‚ â€¢ Tricuspid regurgitation impact       â”‚
â”‚ â€¢ RV-LV interdependence                â”‚
â”‚ â€¢ Respiratory variation significance    â”‚
â”‚                                         â”‚
â”‚ [Next: RV support protocol â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Comprehensive RV Support Triad (Node I â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’ª EVIDENCE-BASED RV SUPPORT PROTOCOL   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ’§ Preload Optimization[1]**:         â”‚
â”‚ â€¢ **Volume assessment**: Clinical + hemodynamicâ”‚
â”‚ â€¢ **Diuretic therapy**: If volume overloadedâ”‚
â”‚   - Furosemide 20-80mg IV (start low)   â”‚
â”‚   - Monitor response (CVP, UOP, labs)   â”‚
â”‚ â€¢ **Volume repletion**: If underfilled  â”‚
â”‚   - 200-300mL NS boluses, assess responseâ”‚
â”‚                                         â”‚
â”‚ **ğŸ« Afterload Reduction[1]**:          â”‚
â”‚ â€¢ **Oxygenation**: Liberal O2 supplementationâ”‚
â”‚ â€¢ **pH optimization**: Correct acidosis â”‚
â”‚ â€¢ **CO2 management**: Avoid hypercapnia â”‚
â”‚ â€¢ **Inhaled vasodilators**:             â”‚
â”‚   - Nitric oxide 10-40 ppm              â”‚
â”‚   - Inhaled epoprostenol 50ng/kg/min    â”‚
â”‚                                         â”‚
â”‚ **ğŸ’ª Contractility Enhancement[1]**:    â”‚
â”‚ â€¢ **Milrinone**: 0.375-0.75 mcg/kg/min (preferred)â”‚
â”‚   - Inotrope + afterload reduction      â”‚
â”‚   - Monitor for hypotension             â”‚
â”‚ â€¢ **Dobutamine**: 2.5-10 mcg/kg/min     â”‚
â”‚   - Pure inotrope, less vasodilation    â”‚
â”‚ â€¢ **Vasopressor support**: Norepinephrine if hypotensiveâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Monitoring Parameters[1]**:        â”‚
â”‚ â€¢ CVP response to interventions         â”‚
â”‚ â€¢ Cardiac output/index improvement      â”‚
â”‚ â€¢ Mixed venous O2 saturation            â”‚
â”‚ â€¢ End-organ function (renal, hepatic)   â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Advanced PAH Management (2025 Evidence)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« EVIDENCE-BASED PAH THERAPY (2025)    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ’Š Initial Combination Therapy[2]**:  â”‚
â”‚ â€¢ **ERA + PDE5i preferred**: Evidence-basedâ”‚
â”‚ â€¢ Ambrisentan 5-10mg + sildenafil 20mg TIDâ”‚
â”‚ â€¢ Alternative: Macitentan 10mg + tadalafil 40mg dailyâ”‚
â”‚ â€¢ **Avoid monotherapy**: In treatment-naive patientsâ”‚
â”‚                                         â”‚
â”‚ **ğŸ†• Sotatercept Era (2024 Breakthrough)**:â”‚
â”‚ â€¢ **FDA approved March 2024**: Game-changer[2]â”‚
â”‚ â€¢ **Mechanism**: Activin signaling inhibitorâ”‚
â”‚ â€¢ **Dosing**: 0.7mg/kg SC every 21 daysâ”‚
â”‚ â€¢ **Add-on therapy**: To dual/triple backgroundâ”‚
â”‚                                         â”‚
â”‚ **âš¡ Acute Management[2]**:              â”‚
â”‚ â€¢ **Oxygen therapy**: Maintain SpO2 >90%â”‚
â”‚ â€¢ **Diuretics**: Gentle, avoid depletionâ”‚
â”‚ â€¢ **Inhaled therapies**: NO, epoprostenolâ”‚
â”‚ â€¢ **IV prostacyclins**: If refractory   â”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Monitoring Response[2]**:          â”‚
â”‚ â€¢ **6-minute walk distance**: Functional capacityâ”‚
â”‚ â€¢ **WHO functional class**: Clinical statusâ”‚
â”‚ â€¢ **BNP/NT-proBNP**: Prognostic marker  â”‚
â”‚ â€¢ **Echo parameters**: RV function assessmentâ”‚
â”‚                                         â”‚
â”‚ **ğŸš« Contraindicated[2]**:              â”‚
â”‚ â€¢ **Pulmonary vasodilators in Group 2 PH**â”‚
â”‚ â€¢ **Beta-blockers**: May worsen RV functionâ”‚
â”‚                                         â”‚
â”‚ [Next: PAH response evaluation â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Left Heart Disease Optimization
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’” LEFT HEART DISEASE RV PROTECTION     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ’Š GDMT with RV Focus[1]**:           â”‚
â”‚ â€¢ **ACE-I/ARB**: Reduce LV filling pressureâ”‚
â”‚ â€¢ **Beta-blockers**: Carvedilol, metoprolol succinateâ”‚
â”‚ â€¢ **MRA**: Spironolactone 25mg daily    â”‚
â”‚ â€¢ **SGLT2i**: Dapagliflozin 10mg (RV benefits)â”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Volume Management Principles[1]**:  â”‚
â”‚ â€¢ **Treat left HF**: Reduces RV afterloadâ”‚
â”‚ â€¢ **Gentle diuresis**: Avoid over-diuresisâ”‚
â”‚ â€¢ **Monitor response**: BNP, functional statusâ”‚
â”‚ â€¢ **Avoid pulmonary vasodilators**: May worsen outcomeâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Hemodynamic Goals[1]**:            â”‚
â”‚ â€¢ **PCWP**: <18 mmHg optimal           â”‚
â”‚ â€¢ **PA pressure**: Reduce with LV therapyâ”‚
â”‚ â€¢ **Cardiac output**: Maintain with GDMTâ”‚
â”‚                                         â”‚
â”‚ **âš ï¸ Special Considerations[1]**:       â”‚
â”‚ â€¢ **Combined PH**: Pre + post-capillaryâ”‚
â”‚ â€¢ **Pulmonary compliance**: May improve with LV therapyâ”‚
â”‚ â€¢ **Avoid excessive afterload reduction**: May compromise perfusionâ”‚
â”‚                                         â”‚
â”‚ [Next: Response monitoring â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3C â€“ RV Infarction Management
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ RIGHT VENTRICULAR INFARCTION         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ Key Management Principles[1]**:    â”‚
â”‚ â€¢ **Maintain preload**: Essential for RV fillingâ”‚
â”‚ â€¢ **Urgent reperfusion**: Primary PCI preferredâ”‚
â”‚ â€¢ **Avoid nitrates**: Reduce preload dangerouslyâ”‚
â”‚ â€¢ **Monitor for complications**: AV block, arrhythmiasâ”‚
â”‚                                         â”‚
â”‚ **ğŸ’§ Volume Management[1]**:            â”‚
â”‚ â€¢ **IV fluid challenges**: 200-300mL NS aliquotsâ”‚
â”‚ â€¢ **Target CVP**: 15-18 mmHg (higher than typical)â”‚
â”‚ â€¢ **Avoid diuretics**: Unless overt volume overloadâ”‚
â”‚ â€¢ **Monitor response**: CO, BP, UOP    â”‚
â”‚                                         â”‚
â”‚ **âš¡ Reperfusion Strategy[1]**:         â”‚
â”‚ â€¢ **Primary PCI**: Preferred approach   â”‚
â”‚ â€¢ **Target vessel**: Usually RCA       â”‚
â”‚ â€¢ **Thrombolysis**: If PCI unavailable â”‚
â”‚ â€¢ **Time-sensitive**: Early intervention crucialâ”‚
â”‚                                         â”‚
â”‚ **ğŸ’ª Hemodynamic Support[1]**:          â”‚
â”‚ â€¢ **Inotropes**: Dobutamine if low outputâ”‚
â”‚ â€¢ **Avoid vasodilators**: May reduce preloadâ”‚
â”‚ â€¢ **Temporary pacing**: If bradycardia/AV blockâ”‚
â”‚                                         â”‚
â”‚ [Next: Post-reperfusion care â–¶]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Mechanical Circulatory Support (2025 Update)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš™ï¸ ADVANCED MECHANICAL SUPPORT OPTIONS  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ MCS Indications (Evidence-Based)[1]**:â”‚
â”‚ â€¢ **Cardiogenic shock**: RV component   â”‚
â”‚ â€¢ **Refractory RV failure**: Despite optimal medical therapyâ”‚
â”‚ â€¢ **Bridge strategies**: Recovery, transplant, decisionâ”‚
â”‚ â€¢ **Post-cardiotomy**: RV failure post-surgeryâ”‚
â”‚                                         â”‚
â”‚ **ğŸ”§ Device Selection Strategy[1]**:    â”‚
â”‚ â€¢ **Impella RP**: Percutaneous, up to 4L/minâ”‚
â”‚   - Isolated RV failure                â”‚
â”‚   - Short-term support (<14 days)      â”‚
â”‚ â€¢ **CentriMag RVAD**: Surgical, durableâ”‚
â”‚   - Longer support capability          â”‚
â”‚ â€¢ **VA-ECMO**: Biventricular failure    â”‚
â”‚   - Respiratory failure component      â”‚
â”‚ â€¢ **Total artificial heart**: End-stageâ”‚
â”‚                                         â”‚
â”‚ **â±ï¸ Timing Considerations[1]**:        â”‚
â”‚ â€¢ **Early intervention**: Before irreversible damageâ”‚
â”‚ â€¢ **Hemodynamic criteria**: CI <2.0, rising lactateâ”‚
â”‚ â€¢ **End-organ function**: Preserve while possibleâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“ Team Activation[1]**:              â”‚
â”‚ â€¢ **Shock team**: Immediate consultationâ”‚
â”‚ â€¢ **Cardiac surgery**: Device implantationâ”‚
â”‚ â€¢ **Perfusion services**: ECMO capabilityâ”‚
â”‚ â€¢ **Advanced HF**: Long-term planning  â”‚
â”‚                                         â”‚
â”‚ [Next: MCS management â–¶]               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ Advanced PAH Therapies (2025 Breakthrough)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ†• BREAKTHROUGH PAH THERAPIES (2025)    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ’Š Sotatercept Revolution[2]**:       â”‚
â”‚ â€¢ **WinrevairÂ® (sotatercept-csrk)**     â”‚
â”‚ â€¢ **Mechanism**: Activin signaling inhibitorâ”‚
â”‚ â€¢ **Clinical impact**: 84% reduction in death/transplantâ”‚
â”‚ â€¢ **Dosing**: 0.7mg/kg SC every 21 daysâ”‚
â”‚ â€¢ **Add-on therapy**: To existing PAH medicationsâ”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Refractory PAH Management[2]**:    â”‚
â”‚ â€¢ **IV epoprostenol**: Continuous infusionâ”‚
â”‚   - Gold standard for severe PAH       â”‚
â”‚   - Requires central access, pumps     â”‚
â”‚ â€¢ **Inhaled treprostinil**: QID dosing  â”‚
â”‚ â€¢ **Selexipag**: Oral prostacyclin pathwayâ”‚
â”‚                                         â”‚
â”‚ **ğŸ«€ Advanced Interventions[2]**:       â”‚
â”‚ â€¢ **Balloon atrial septostomy**: Create Râ†’L shuntâ”‚
â”‚ â€¢ **Potts shunt**: Pulmonary-aortic anastomosisâ”‚
â”‚ â€¢ **Lung transplantation**: Ultimate therapyâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“Š Risk Stratification Tools[2]**:    â”‚
â”‚ â€¢ **REVEAL Risk Score**: Mortality predictionâ”‚
â”‚ â€¢ **WHO Functional Class**: Symptom severityâ”‚
â”‚ â€¢ **6MWD + BNP**: Combined prognostic valueâ”‚
â”‚                                         â”‚
â”‚ [Next: Long-term management â–¶]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Bridge to Recovery vs Advanced Care
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸŒ‰ BRIDGE DECISION FRAMEWORK            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ”„ Bridge to Recovery Indicators[1]**: â”‚
â”‚ â€¢ **Reversible etiology**: PE, myocarditis, drug-inducedâ”‚
â”‚ â€¢ **Young age**: <50 years with good baselineâ”‚
â”‚ â€¢ **Acute presentation**: Recent onset RHFâ”‚
â”‚ â€¢ **Improving hemodynamics**: Response to therapyâ”‚
â”‚                                         â”‚
â”‚ **ğŸ«€ Bridge to Advanced Therapy[1]**:    â”‚
â”‚ â€¢ **End-stage PAH**: Refractory to medical therapyâ”‚
â”‚ â€¢ **Chronic RV dysfunction**: Irreversible damageâ”‚
â”‚ â€¢ **Recurrent decompensation**: Frequent hospitalizationsâ”‚
â”‚ â€¢ **Transplant candidate**: Meeting criteriaâ”‚
â”‚                                         â”‚
â”‚ **âš–ï¸ Decision Factors[1]**:             â”‚
â”‚ â€¢ **Underlying pathophysiology**: Reversible vs progressiveâ”‚
â”‚ â€¢ **Functional status**: Baseline quality of lifeâ”‚
â”‚ â€¢ **Age and comorbidities**: Surgical risk assessmentâ”‚
â”‚ â€¢ **Social support**: Long-term care capabilityâ”‚
â”‚                                         â”‚
â”‚ **ğŸ¯ Goals of Care Discussion[1]**:     â”‚
â”‚ â€¢ **Quality vs quantity**: Patient values alignmentâ”‚
â”‚ â€¢ **Functional goals**: Realistic expectationsâ”‚
â”‚ â€¢ **Family involvement**: Shared decision-makingâ”‚
â”‚                                         â”‚
â”‚ [Next: Appropriate disposition â–¶]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6 â€“ Comprehensive Quality Metrics (Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š RHF QUALITY MANAGEMENT & OUTCOMES    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ **ğŸ¯ Process Excellence Metrics**:      â”‚
â”‚ â€¢ **Echo completion**: <2h from recognition (>90%)â”‚
â”‚ â€¢ **Etiology identification**: Within 4h (>85%)â”‚
â”‚ â€¢ **Swan-Ganz placement**: <4h if indicated (>80%)â”‚
â”‚ â€¢ **PAH specialist consultation**: Same day (>75%)â”‚
â”‚                                         â”‚
â”‚ **ğŸ“ˆ Clinical Outcome Measures**:       â”‚
â”‚ â€¢ **30-day mortality**: <20% acute RHF  â”‚
â”‚ â€¢ **ICU length of stay**: <7 days medianâ”‚
â”‚ â€¢ **Readmission rate**: <25% at 30 days â”‚
â”‚ â€¢ **Functional improvement**: 6MWD >30m increaseâ”‚
â”‚                                         â”‚
â”‚ **ğŸ”§ MCS Quality Indicators**:          â”‚
â”‚ â€¢ **Appropriate MCS selection**: >90% concordanceâ”‚
â”‚ â€¢ **Time to MCS**: <6h for indicated casesâ”‚
â”‚ â€¢ **MCS weaning success**: >60% bridge to recoveryâ”‚
â”‚ â€¢ **Complication rates**: <10% device-relatedâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“‹ PAH-Specific Metrics**:            â”‚
â”‚ â€¢ **Combination therapy initiation**: >80% appropriate patientsâ”‚
â”‚ â€¢ **Sotatercept access**: High-risk PAH patientsâ”‚
â”‚ â€¢ **WHO functional class improvement**: >70%â”‚
â”‚                                         â”‚
â”‚ **ğŸ”„ Continuous Improvement**:          â”‚
â”‚ â€¢ **Monthly case reviews**: Multidisciplinaryâ”‚
â”‚ â€¢ **Quarterly outcome analysis**: Benchmarkingâ”‚
â”‚ â€¢ **Annual protocol updates**: Evidence integrationâ”‚
â”‚                                         â”‚
â”‚ **ğŸ“š Team Education & Training**:       â”‚
â”‚ â€¢ **RHF recognition training**: All RRT membersâ”‚
â”‚ â€¢ **Hemodynamic interpretation**: Physician competencyâ”‚
â”‚ â€¢ **MCS decision-making**: Advanced HF trainingâ”‚
â”‚                                         â”‚
â”‚ âœ… **ENHANCED RHF PROTOCOL COMPLETE**   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: All Treatment Pathways]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES ENHANCED IMPLEMENTATION

### **Evidence-Based Integration (2025)**:
- **UpToDate Clinical Guidelines**: Comprehensive RHF management protocols[1][2]
- **Systematic Etiology Classification**: Five-group PH classification system
- **Advanced PAH Therapies**: Sotatercept integration for breakthrough management
- **Hemodynamic Monitoring**: Swan-Ganz catheter optimization protocols

### **Advanced Diagnostic Protocols**:
- **Point-of-Care Echocardiography**: RV function assessment within 2 hours
- **Hemodynamic Monitoring**: Swan-Ganz catheter for unstable patients
- **Advanced Imaging**: Cardiac MRI for complex cases, CT-PA for PE evaluation
- **Biomarker Integration**: BNP/NT-proBNP for risk stratification

### **Technology-Enhanced Care**:
- **Hemodynamic Calculators**: Automated PVR, cardiac output calculations
- **Risk Stratification Tools**: REVEAL score integration
- **MCS Decision Support**: Algorithm-driven device selection
- **Quality Dashboards**: Real-time metric tracking and benchmarking

### **Team-Based Excellence**:
- **Rapid Response Integration**: 24/7 advanced HF and PAH specialist availability
- **Multidisciplinary Rounds**: Daily team assessment with hemodynamic review
- **MCS Committee**: Device selection and management optimization
- **Outcomes Research**: Continuous quality improvement through data analysis

### **Patient-Centered Outcomes**:
- **Functional Improvement Focus**: 6-minute walk distance, WHO functional class
- **Quality of Life Emphasis**: Patient-reported outcome measures
- **Family Involvement**: Shared decision-making in complex cases
- **Long-term Follow-up**: Specialized RHF clinic development

## REFERENCE GUIDELINES & EVIDENCE BASE
- **UpToDate Right Heart Failure Management**: Comprehensive evidence-based protocols[1]
- **UpToDate PAH Treatment Guidelines**: Advanced therapy integration[2]
- **2024 PAH Breakthrough Therapies**: Sotatercept and novel agents
- **Virtua Health System RHF Protocol v2025**: Enhanced evidence integration

**This enhanced protocol represents the most comprehensive integration of evidence-based right heart failure management, incorporating the latest therapeutic advances, advanced hemodynamic monitoring, and technology-enhanced care delivery optimized for superior patient outcomes at Virtua Voorhees.**
